|
|
|
|
|
|
|
|
|
|
Conclusions: "Our ROC analysis did not demonstrate any reliable CA-125 cutoff on response. Discontinuation of the therapy before cycle 3 may exclude some patients who will benefit from PLD."
Wednesday, January 13, 2010
CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
Conclusions: "Our ROC analysis did not demonstrate any reliable CA-125 cutoff on response. Discontinuation of the therapy before cycle 3 may exclude some patients who will benefit from PLD."
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.